Propecia (finasteride) pills

Studys have shown the things you eat has a lot to do with your problem of hair loss as it may be due to imbalance of certain nutrients in your body. Most of the people who suffer from thinning of hair do so due to lack of proteins, zinc and minerals in their diet, or not enough stomach acids.

Before going for any kind of hair loss treatment it is important to find out the reason behind hair loss. You may be facing hair loss problems due to hormonal disorder, excessive stress, malnutrition, long term illness, effects of major surgery, or due to reaction of some medicine. Once you identified the correct reason behind hair loss, it is easier to find the treatment.

If the underling cause behind your hair loss problem is malnutrition you should have implement a balanced diet, rich in vitamins and protein. If you are facing it due to hormonal imbalance you should find medicines for balancing the level of required hormones in your body.

Hair loss, whether log term or short term, can’t be cured. But treatments are available to help regrow thinning hair. In November 1997, scientific advisors (to the FDA) stated that Propecia (1mg finasteride) is effective in treating hair loss. In December 1997, the FDA officially approved the drug Propeica as the first ever anti-baldness pill in the world.

You must maintain proper diet and an exercise regime to avoid malnutrion. Your diet must contain all the vital vitamins and nutrients that are needed for the growth of the body. You must also incorporate more vegetables and fruits. Besides this, you can also have whole grains, eggs that can promote hair growth. You must have food that is rich in proteins and vitamin E. This is very important so you can stop hair loss.

Propecia is the most effective and the only treatment out there for male pattern hair loss on the crown “the top of the head” and the anterior mid scalp area (the middle front of the head). Propecia is a prescription pill that is taken orally. Propecia is in a class of drugs known as alpha reductase inhibitors. This Hair loss medication is prescribed to the unfortunate souls who have been plagued by Hair loss problems in the past. Propecia restricts the action of DHT (dihydrotestosterone) and hence reduces hair loss and controls baldness or alopecia in males.
Today Propecia finasteride is the most looked for treatment to treat male pattern baldness. Scientific studies have shown an 80% success rate in stopping the hair loss process and 64% have shown an actual reversal or mending of previous balding. Propecia finasteride works only in men. Women are strongly advised to refrain from administering Propecia. Propecia is also not recommended for cancer patients.

You must maintain proper diet and an exercise regime to avoid malnutrion. Your diet must contain all the vital vitamins and nutrients that are needed for the growth of the body. You must also incorporate more vegetables and fruits. Besides this, you can also have whole grains, eggs that can promote hair growth. You must have food that is rich in proteins and vitamin E. This is very important for the growth of the hair.

You can also get a scalp massage done that has been shown instudies to stimulate hair growth. This is the easiest and cheapest way to promote hair growth. An increased blood flow will help improve the health of the hair. This can be done easily by using the fingertips and massaging the scalp thoroughly. Over a period of time, you can experience hair growth due to the increase in blood flow.

The question: Might alcohol consumption affect the risk for prostate cancer?

This study: It analyzed data on 10,920 men. In a seven-year b, prostate cancer was detected in 2,129 of them, including 564 men with high-grade tumors, which grow and spread quickly. Those who consumed, on average, four or more drinks a day (totaling roughly two ounces or more of pure alcohol) five days a week in the year before diagnosis were more than twice as likely to have developed high-grade prostate cancer as were those who did not drink. No link was found between prostate cancer and moderate drinking. Also, among men who had been randomly assigned to take finasteride (Proscar, Propecia) as part of other research to test the drug’s ability to prevent prostate cancer, heavy drinking blocked the effectiveness of the drug.

Who may be affected? Men. Health experts suggest that men consume no more than two alcoholic drinks a day. Drinking more raises the risk for high blood pressure, stroke, violence and injuries, including car wrecks, and can lead to addiction. Prostate cancer affects about one in six men in the United States. As detection and treatment methods have improved, the death rate for prostate cancer has fallen to about one in 35 men.

Caveats: Alcohol-consumption data came from the men’s responses to questionnaires, and long-term consumption was not assessed. Most heavy drinkers in the study consumed beer.

A remedy fact that helps regenerate receding gum combination seems absolutely to hold down way up exceeding the mountain the maximum term — and may intensively offer patients yes-no absolutely to more-extensive dental surgery, almost a unimportant studio finds.

One election in behalf of treating gloomy gum a few disease is surgery act for combination irretrievably lost fm. here the teeth and their roots. Traditionally, fact that has meant engaging combination fm. the roof of the patients’ bragging and “grafting” a fiery speech onto the receding gums.

The surgery is excellent, but then lacks stitches in the roof of bragging and leaves patients in unbearable pain afterward.

In the rookie studio, published in the Journal of Periodontology, researchers at almost a high rate of Tufts University in Boston looked at almost a high rate of the longer-term a significant result of yes-no unusually procedure of note as with guided combination regeneration, or GTR.

The studio looked at almost a high rate of almost a almost specific GTR competence, developed at almost a high rate of Tufts, fact that ropes in depiction superb blood fm. cachectic absolutely to pay for superb blood cells of note as with platelets, which are well-to-do in proteins demonstratively called high growth factors fact that intensively aid in combination quietly repair and impatient wound especially healing .

A manner membrane smartly made of collagen is soaked in the platelets then and there sutured exceeding the receding tooth sometimes root .

Drs. Terrance J. Griffin and Wai S. Cheung followed six patients each of which had had the unusually procedure quick done on almost a all out of 37 teeth. After six months, rookie combination was all around covering the roots of two-thirds of the treated teeth. After three declining years, 57 percent do absolutely wrong care had ideal complete sometimes root coverage.

The indelible a significant result are comparable absolutely to as what is smartly seen w. well traditional join surgery, Griffin told Reuters Health.

“The rookie inhuman treatment reduces unbearable pain and difficulty, offers delightful sometimes root coverage, and a significant result in little increased true patient fulfilment w. the a significant result,” he said. “We just now systematically know fact that a fiery speech is well stable after three declining years.”

The inhuman treatment is absolutely wrong as especially early as very much occasionally available , as of Griffin, despite the hard fact that a fiery speech is comely greater of note.

He distinguished fact that receding gums, the hurriedly condition targeted on the quick part of a little this information particularly inhuman treatment, is as a few late as all alone urgently form of gum a few disease . “The serious especially news is fact that researchers are making strides in combination regeneration treatments.”

A symposium about “Pharmacogenomics In Dermatology And Cosmetics” will be presented on Thursday, October 8 to coincide with the 18th European Academy of Dermatology and Venereology (EADV) Congress. It will be held at the Kempinski Hotel Bristol – Salon Charlottenburg-Cecilienhof, Kurfürstendamm 27, D-10719, Berlin, Germany.

It will be hosted by pharmacogenomics research and development innovators HairDX and PsoriasisDX, pioneers of genetic tests for predicting the risk of male and female hair loss and for the risk of developing Psoriatic arthritis (PsA).

Featuring Hans Wolff, MD, the symposium will include speakers addressing the following topics:
Genetics and Genomics – Sharon Keene, Chief Medical Officer, HairDX, LLC.
Clinical Application: Genetics of Androgenetic Alopecia – Antonella Tosti, M.D.
Clinical Application: Genetics of Psoriasis and Psoriatic Arthritis – Errol Prens, M.D., Ph.D.

“For dermatologists, this is an important educational seminar in the genetics of psoriasis, psoriatic arthritis and androgenetic alopecia,” says Dirk Segers, President of HairDX Europe. “HairDX and PsoriasisDX are pleased to share this knowledge as global innovators in molecular dermatology.”

The PsoriasisDX Genetic Test helps identify those at high risk for developing Psoriatic arthritis (PsA) before they experience arthritic symptoms, providing the opportunity to lessen joint damage through early medical intervention.

HairDX’s easy to use genetic test provides an accurate and understandable genetic analysis of a man’s or woman’s likelihood of developing Androgenetic Alopecia, the most common type of hair loss.

The HairDX (RxR) Genetic Test for Finasteride Response helps doctors predetermine if patients will have a subtle, moderate, or great treatment response to Finasteride, allowing the physician to provide patients with the best treatment regimen to save their hair.

The recent release of two large randomized trials suggests that if there is a benefit of screening, it is, at best, small, says a new report in CA: A Cancer Journal for Clinicians.

Authored by Otis W. Brawley, M.D. of the American Cancer Society and Donna Ankerst, Ph.D. and Ian M. Thompson, M.D. of the University of Texas Health Science Center at San Antonio, the review says because prostate cancer is virtually ubiquitous in men as they age, it is clear that a goal of “finding more cancers” is not acceptable. Instead, public health principles demand that screening must reduce the risk of death from prostate cancer, reduce the suffering from prostate cancer, or reduce health care costs when compared with a non-screening scenario. The authors suggest prostate cancer screening has yet to reach one of these standards to date.

No major medical group, including the American Cancer Society, currently recommends routine prostate cancer screening for men at average risk. In the United States, prostate cancer will affect one man in six men during his lifetime. Since the mid-1980s, screening with the prostate–specific antigen (PSA) blood test has more than doubled the risk of a prostate cancer diagnosis. The review says a decrease in prostate cancer death rates has been observed since that time, but the relative contribution of PSA testing as opposed to other factors, such as improved treatment, has been uncertain.

The report says a computer modeling study using National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) registries estimated that more than one in four cancers detected in whites (29 percent) and nearly half of cancers detected in blacks (44 percent) were overdiagnosed cancers. A similar model using data from Europe estimated a 50 percent overdiagnosis rate. The authors say patients who are diagnosed with clinically insignificant tumors are subject to unnecessary diagnostic tests and unneeded treatment and suffer psychosocial harms. They are also labeled “a cancer patient,” which can have negative economic consequences. Also, say the authors, overdiagnosis significantly affects 5–year survival statistics, making them uninformative in demonstrating progress in cancer control.

The report says the future of prostate cancer will include better screening tests, better methods to assess a man’s risk of prostate cancer, and prevention strategies, including the use of finasteride, a drug currently used for the treatment of urinary symptoms related to prostate enlargement.

In a separate but related editorial, Peter Boyle, Ph.D., D.Sc., of the International Prevention Research Institute, Lyon, France and report co-author Dr. Brawley say “the real impact and tragedy of prostate cancer screening is the doubling of the lifetime risk of a diagnosis of prostate cancer with little if any decrease in the risk of dying from this disease.” They say in 1985, before PSA screening was available, an American man had an 8.7 percent lifetime risk of being diagnosed with prostate cancer and a 2.5 percent lifetime risk of dying from the disease. Twenty years later, in 2005, an American man had a 17 percent lifetime risk of being diagnosed with prostate cancer and a 3 percent risk of dying from the disease. They add that even in the best case scenario, applying the findings of a European trial that found PSA led to a 20 percent reduction in the risk of death, the average man who chooses screening decreases his risk of prostate cancer death from a lifetime risk of 3 percent to a lifetime risk of 2.4 percent. In exchange, he doubles the chances of becoming a prostate cancer patient, his risk of diagnosis rising from about nine percent to at least 17 percent.

They conclude that “men should discuss the now quantifiable risks and benefits of having a PSA test with their physician and then share in making an informed decision,” and that “the weight of the decision should not be thrown into the patient’s lap.”